What is the recommended weekly dosing schedule for methotrexate in rheumatoid arthritis or psoriasis, including starting dose, titration increments, maximum dose, route considerations, folic acid supplementation, and monitoring parameters?

Methotrexate Dosing for Rheumatoid Arthritis and Psoriasis

Starting Dose

For rheumatoid arthritis, initiate methotrexate at 15 mg weekly and titrate to at least 15 mg within 4-6 weeks; for psoriasis, start at 10-15 mg weekly with a typical range of 7.5-25 mg weekly. 1, 2

Rheumatoid Arthritis

• Starting dose should not be less than 10 mg/week 1
• The 2021 ACR guideline conditionally recommends initiation/titration to at least 15 mg weekly within 4-6 weeks over lower doses 1
• This recommendation balances increased efficacy against toxicity risk, though it remains conditional due to wide variation in physician and patient preferences 1

Psoriasis

• Recommended dosage typically ranges from 7.5 to 25 mg weekly 2
• FDA labeling suggests 10-25 mg per week as the starting range 3
• A test dose of 2.5-5 mg should be considered, especially in patients with impaired kidney function 2

Route of Administration

Start with oral methotrexate, but switch to subcutaneous administration if there is inadequate response, gastrointestinal intolerance, or compliance issues. 1, 2

• Oral methotrexate is conditionally recommended over subcutaneous for initial therapy 1
• Despite moderate evidence showing superior efficacy of subcutaneous injections, oral administration is preferred due to ease of use and similar bioavailability at typical starting doses 1
• Switch to subcutaneous methotrexate when: 1
  • Patient not at target on oral therapy
  • Gastrointestinal side effects develop
  • Poor compliance occurs
  • Doses exceed 15-20 mg/week (absorption may be better parenterally)

Dose Titration

Increase methotrexate by 2.5-5 mg every 4-6 weeks until achieving therapeutic response, up to a maximum of 20-25 mg weekly. 1, 3

Rheumatoid Arthritis

• Escalate at 6-week intervals up to 20 mg/week according to tolerance 1
• Further dose escalation often provides additional efficacy 1
• Maximum dose: 20 mg/week is the practical upper limit - doses above this significantly increase serious toxicity risk, especially bone marrow suppression 3

Psoriasis

• Adjust gradually to achieve optimal clinical response 3
• 30 mg/week should not ordinarily be exceeded 3
• Dosage changes typically require at least one month for clinical response 2

Split Dosing Strategy

For patients with gastrointestinal intolerance, administer methotrexate as 3 divided doses over 24 hours (e.g., every 12 hours). 1, 2

• Split dosing of oral methotrexate over 24 hours is conditionally recommended over switching DMARDs for patients not tolerating weekly oral methotrexate 1
• The dose can be given as a single dose or in 3 doses over 24 hours 2

Folic Acid Supplementation

Prescribe folic acid 5 mg once weekly (on a different day than methotrexate) or 1 mg daily (except on methotrexate day) to reduce gastrointestinal and hepatic adverse effects. 2

• Administration of folic acid or folinic acid is strongly recommended (Grade A) to reduce incidence of GI and hepatic adverse effects 2
• Typical dosing: minimum 5 mg once weekly at a distance from the methotrexate dose 4
• Alternative: Daily folic acid except on methotrexate administration days 2
• Caution: Large folic acid doses may reduce methotrexate efficacy 2
• Recent evidence suggests high-dose folic acid (≥5 mg daily) may be associated with increased cardiovascular risk 5

Monitoring Parameters

Obtain CBC, liver function tests, and creatinine at baseline, then monthly for 3 months, then every 4-12 weeks thereafter. 2, 4

Baseline Assessment (Pre-Methotrexate)

• Complete blood count (CBC)
• Serum transaminases (AST/ALT)
• Serum creatinine with creatinine clearance calculation
• Chest radiograph
• Recommended: Hepatitis B and C serologies, serum albumin 4
• Noninvasive liver fibrosis assessment (not liver biopsy) 2
• For patients with respiratory history/symptoms: lung function tests with DLCO 4

Ongoing Monitoring

• CBC, liver enzymes, creatinine: 2, 4
  • At least once monthly for first 3 months
  • Then every 4-12 weeks
• Liver function tests every 3-6 months assuming no abnormalities 2
• For abnormal elevations: repeat in 2-4 weeks; if persistent, refer to GI specialist 2

Risk Factors for Hepatotoxicity

Monitor more closely if patient has: 2

• Type 2 diabetes or obesity (significant risk factors)
• Alcohol use (>1 drink/day for women, >2 drinks/day for men)
• Chronic liver disease (hepatitis B or C)
• Prior hepatotoxic drug exposure
• Family history of inheritable liver disease

Common Pitfalls to Avoid

1. Do not use daily dosing - weekly dosing is superior and has lower hepatotoxicity 2
2. Do not give folic acid on the same day as methotrexate - separate by at least 24 hours to avoid reducing efficacy
3. Do not start at doses <10 mg/week in RA - this delays therapeutic response without meaningful safety benefit 1, 4
4. Do not perform baseline liver biopsy - noninvasive assessment is preferred 2
5. Do not administer leucovorin intrathecally 3
6. Ensure contraception in women of childbearing age - methotrexate is absolutely contraindicated in pregnancy; wait at least 3 months after discontinuation before attempting conception 2

Special Considerations

• Therapeutic response typically begins within 3-6 weeks, with continued improvement for up to 12 weeks 3
• When methotrexate is discontinued, arthritis usually worsens within 3-6 weeks 3
• Maximal myelosuppression occurs in 7-10 days after dosing 3
• For patients with impaired renal function (creatinine clearance <60 mL/min), methotrexate is contraindicated for high-dose regimens 3